A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, providing durable and even curative responses. However, most patients do not respond and current biomarkers (eg, programmed death 1 ligand 1 [PD-L1]), mismatch repair deficiency [dMMR]/high microsatellite i...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2026-01-01
|
| Col·lecció: | Journal of Translational Medicine |
| Accés en línia: | https://doi.org/10.1186/s12967-025-07378-2 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
